Related Experiment Video
Updated: Jun 27, 2025
05:26
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
Published on: September 16, 2022
3.9K
Circulating tumor DNA in liquid biopsy: Current diagnostic limitation
1School of Medical Information, Wannan Medical College, Wuhu 241002, Anhui Province, China. liushicainj@163.com.
World Journal of Gastroenterology
|April 29, 2024
Summary
Cell-free DNA (cfDNA) shows promise as a biomarker for cancer diagnosis and monitoring. Further research into circulating tumor DNA (ctDNA) origins and dynamics is crucial for advancing precision medicine.
Area of Science:
- Biomarkers
- Molecular Diagnostics
- Oncology
Background:
- Cell-free DNA (cfDNA) is increasingly recognized as a vital biomarker in oncology.
- cfDNA, including circulating tumor DNA (ctDNA), offers non-invasive insights into tumor status.
- Liquid biopsy technologies based on cfDNA hold significant potential for precision medicine.
Discussion:
- Current limitations exist in analyzing the origins and dynamics of ctDNA.
- Addressing these limitations is key to fully harnessing ctDNA's potential.
- Understanding ctDNA shedding and clearance is critical for accurate monitoring.
Key Insights:
- cfDNA serves as a non-invasive tool for cancer detection and prognosis.
- ctDNA analysis provides a window into tumor biology and treatment response.
- The development of cfDNA-based liquid biopsies is advancing cancer care.
Outlook:
- Future research should focus on overcoming current analytical challenges in ctDNA studies.
- Refined ctDNA analysis will enhance its role in personalized cancer treatment.
- Continued innovation in cfDNA detection promises improved patient outcomes.
